Home > News > Recent cases

32Red v WHG8 May 2013Lindsay Lane and Tom Moody-Stuart recently appeared before Mr Justice Newey in 32Red v WHG, Lindsay Lane appearing with Henry Carr QC for WHG and Tom Moody-Stuart appearing with Michael Silverleaf QC for 32Red. The case concerned a damages inquiry following a successful Trade Mark infringement liability hearing in October 2010. By trial it was […]
Public Relations Consultants Association Ltd v The Newspaper Licensing Agency Ltd [2013] UKSC 1823 April 2013Andrew Lykiardopoulos recently appeared in the Supreme Court, led by Henry Carr QC in The Newspaper Licensing Agency Limited v. Meltwater & the PRCA [2013] UKSC 18. The case concerned whether viewing or reading a web page could amount to copyright infringement. In particular, the case concerned the scope of the temporary copying exception to […]
Merck Canada Inc v Sigma Pharmaceuticals PLC [2013] EWCA Civ 32618 April 2013Martin Howe QC and Isabel Jamal acted for the appellants in successfully persuading the Court of Appeal to make a preliminary reference on the interpretation of the so-called ‘Specific Mechanism’, which relates to the parallel importation of pharmaceuticals from Poland and other EU Accession States. The case was decided at first instance ([2012] EWPCC 18, […]
Lizzano Partitions (UK) Limited v Interiors Manufacturing Limited [2013] EWPCC 1211 April 2013Isabel Jamal recently appeared before His Honour Judge Birss QC in the Patents County Court in Lizzanno Partitions (UK) Limited v Interiors Manufacturing Limited [2013] EWPCC 12. She acted for the patentee who succeeded in defending an action for a declaration of non-infringement (in relation to which it brought a counterclaim for infringement) and a […]
Hospira UK Ltd v Novartis AG [2013] EWHC 516 (Pat)2 April 2013Michael Tappin QC recently acted for Generics (UK) Ltd (t/a Mylan), the second claimant in Hospira UK Ltd v Novartis AG [2013] EWHC 516 (Pat). This was a claim for revocation of two European patents relating to the intravenous administration of zoledronate for the treatment of osteoporosis, at intervals of at least six months. The […]